IBB:NSD-iShares Biotechnology ETF (USD)

ETF | Health |

Last Closing

USD 142.61

Change

-2.19 (-1.51)%

Market Cap

USD 7.60B

Volume

0.81M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-03 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
PPH VanEck Pharmaceutical ETF

-0.76 (-0.81%)

USD 0.72B
BBH VanEck Biotech ETF

-2.29 (-1.30%)

USD 0.45B
PSCH Invesco S&P SmallCap Health Ca..

-0.69 (-1.53%)

USD 0.20B
PTH Invesco DWA Healthcare Momentu..

-0.48 (-1.05%)

USD 0.15B
GNOM Global X Genomics & Biotechnol..

-0.24 (-2.16%)

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti..

-0.25 (-0.86%)

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET..

-0.22 (-1.49%)

USD 0.01B

ETFs Containing IBB

IBB3:LSE 300.12 % 0.00 %

N/A

N/A
HAC.A:CA 0.00 % 3.14 %

N/A

N/A
HAC:CA Global X Seasonal Rotatio.. 0.00 % 1.27 %

-0.05 (0%)

CAD 0.22B
IBBS:LSE -299.94 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.98% 38% F 60% D-
Dividend Return 0.24% 60% D- 3% F
Total Return 5.22% 38% F 57% F
Trailing 12 Months  
Capital Gain 17.10% 50% F 63% D
Dividend Return 0.37% 50% F 4% F
Total Return 17.47% 50% F 60% D-
Trailing 5 Years  
Capital Gain 43.28% 63% D 69% C-
Dividend Return 1.60% 43% F 5% F
Total Return 44.88% 50% F 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 3.53% N/A N/A 53% F
Dividend Return 3.76% N/A N/A 50% F
Total Return 0.24% N/A N/A 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 20.02% N/A N/A 76% C+
Risk Adjusted Return 18.78% N/A N/A 53% F
Market Capitalization 7.60B 100% F 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike